Meetings

2018 Schedule and Program for the ASH Meeting on Lymphoma Biology

The following programming corresponds to the 2018 ASH Meeting on Lymphoma Biology.

Thursday - August 2

2:00 p.m. - 7:00 p.m.	Registration
5:00 p.m. – 5:20 p.m.	Welcome, Introduction, and Announcements Program Co-Chairs: Riccardo Dalla-Favera, MD, Columbia University Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania Freda K. Stevenson, DPhil, University of Southampton Medical School
5:20 p.m. – 6:05 p.m.	Opening Keynote Address Michael Reth, PhD, University of Freiburg B Cell Antigen Receptor Signaling of Normal and Transformed B Cells
6:05 p.m. – 8:00 p.m.	Welcome Reception and Exhibits

Friday - August 3

7:00 a.m. – 5:00 p.m.	Registration
7:00 a.m. – 8:00 a.m.	Breakfast and Exhibits
8:00 a.m. – 10:00 a.m.	The Germinal Center as the Target Site Chair: Riccardo Dalla-Favera, MD, Columbia University Speakers: Shane Crotty, PhD, La Jolla Institute for Allergy and Immunology T Follicular Helper (Tfh) CD4 T cells, Germinal Centers, Immunodominance, and the Generation of Memory to Vaccines David Dominguez-Sola, MD, PhD, Icahn School of Medicine at Mount Sinai Germinal Center Dynamics in the Pathogenesis of B cell non-Hodgkin Lymphomas Stefano Casola, MD, PhD, International Foundations of Medicine Targeting BCR Function in Mature B-Cell Neoplasms: Opportunities, Challenges, and Warnings: Lessons From Mouse Models Oral Abstract Presenters: Katia Basso, PhD, Columbia University MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis Vipul Shukla, PhD, La Jolla Institute for Allergy and Immunology Tet Proteins Regulate Enhancer Function and Class Switch Recombination During B Cell Activation
10:00 a.m. – 10:15 a.m.	Networking Coffee Break
10:15 a.m. – 12:15 p.m.	Microenvironment Influences in Lymphoma Chair: Freda K. Stevenson, DPhil, University of Southampton Medical School Speakers: Hans-Guido Wendel, MD, Memorial Sloan Kettering Cancer Center Immune Receptor Mutations in Lymphoma Karin Tarte, PhD, INSERM U1236 & CHU Rennes Follicular Lymphoma Cell Niche: Role and Heterogeneity of FL-CAF Ron Levy, MD, Stanford School of Medicine Combining Intratumoral Injections of Toll-Like Receptor Agonists With Checkpoint Antibodies Oral Abstract Presenters: Elena Viganò, PhD, BC Cancer Research Centre Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition Olga Kutovaya, PhD, BC Cancer Research Centre UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation Through a Cyclin D1-Dependent Mechanism
12:15 p.m. – 1:15 p.m.	Lunch and Exhibits
1:15 p.m. – 1:45 p.m.	Company Presentations (Cancelled) Free Time
1:45 p.m. – 4:00 p.m.	Continuing Conversations Moderator: Francesco Forconi, MD, PhD Continuing Conversation on B-Cell Receptor-Associated Kinase Inhibition in Tumor and Normal B Cells in vivo and in vitro Moderator: Silvia Deaglio, MD, PhD Continuing Conversation on Chronic Lymphocytic Leukemia Microenvironment and its Relevance for Tumor Progression Moderators: Laura Pasqualucci, MD and Ari Melnick, MD Continuing Conversation on Epigenetic Mechanisms in Lymphoma – What are the Biggest Unanswered Questions? Moderator: David Dominguez-Sola, MD, PhD Continuing Conversation on Germinal Center Biology, Dynamics and B cell Lymphomagenesis Moderator: Megan Lim, MD, PhD Continuing Conversation on Mass Spectrometry-based Proteomics in the Identification of Novel Biologic Insights in T-cell Lymphomas Moderator: Andreas Strasser, MSc, PhD, FAA Continuing Conversation on the Tumor Suppressor p53 – How Does it Prevent Cancer and How Can Mutant p53 be Targeted Therapeutically?
4:00 p.m. – 5:30 p.m.	Poster Presentations
5:30 p.m. – 7:00 p.m.	Dinner (provided)
7:00 p.m. – 9:00 p.m.	Discovery of Novel Pathogenic Mechanisms and Therapies in Lymphoma Chair: Ari Melnick, MD, Weill Cornell Medical College Speakers: Ari Melnick, MD, Weill Cornell Medical College Harnessing the Epigenome for Immunotherapy of B-cell Lymphoma Laura Pasqualucci, MD, Columbia University Genetic Basis of Epigenetic Dysregulation in Germinal Center-Derived Lymphomas Suzanne Cory, PhD, Walter and Eliza Hall Institute of Medical Research From Translocation to Therapy: How Understanding the BCL-2 Cell Life/Death Switch Is Leading to More Effective Therapy Oral Abstract Presenter: Justin Taylor, MD, Memorial Sloan Kettering Cancer Center Oncogenic Mutations in XPO1 Promote Lymphoid Transformation by Altering Nuclear-Cytoplasmic Localization of NFκB Signaling Intermediates Ryan M. Young, PhD, National Cancer Institute, National Institutes of Health Functional Proteogenomic Screens Reveal a Myd88-TLR9 B Cell Receptor Supercomplex in Diffuse Large B-Cell Lymphoma

Saturday - August 4

7:00 a.m. – 5:00 p.m.	Registration
7:00 a.m. – 8:00 a.m.	Breakfast and Exhibits
8:00 a.m. – 9:45 a.m.	New Technologies and Diagnostics Chair: Ash A. Alizadeh, MD, PhD, Stanford University Medical Center Speakers: Michael Angelo, MD, PhD, Stanford University Single Cell Analysis of Signaling Ronald N. Germain, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health Single Cell Imaging Ash A. Alizadeh, MD, PhD, Stanford University Medical Center Circulating Tumor DNA Oral Abstract Presenter: Daniel J. Hodson, MD, PhD, University of Cambridge Engineering the Genetics Events of Lymphomagenesis in Normal Human B Cells for High-Throughput, Functional Prioritization of Lymphoma Driver Genes
9:45 a.m. – 10:00 a.m.	Networking Coffee Break
10:00 a.m. – 12:00 noon	Molecular Targeting Chair: Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health Speakers: Anthony Letai, MD, PhD, Dana-Farber Cancer Institute Mitochondria Tell You What You Need to Know to Treat Lymphoid Cancers Andreas Strasser, MSc, PhD, FAA, Walter and Eliza Hall Institute of Medical Research How Does the Tumor Suppressor p53 Protect Us From Developing Cancer? Roberto Chiarle, MD, Boston Children's Hospital Targeted Therapy and Resistance in Lymphoma Oral Abstract Presenters: Guangzhen Hu, PhD, Mayo Clinic Targetability of Novel STAT3-JAK2 Fusions Identified in T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract Daniel J. Landsburg, MD, Abramson Cancer Center A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated With the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients With MYC-Altered Disease
12:00 noon – 1:00 p.m.	Lunch and Exhibits
1:00 p.m. – 1:30 p.m.	Company Presentations (Cancelled) Free Time
1:30 p.m. – 3:15 p.m.	Molecular Targeting (continued) Chair: Margaret A. Shipp, MD, Dana-Farber Cancer Institute Speakers: Margaret A. Shipp, MD, Dana-Farber Cancer Institute Targetable Genetic Signatures in Lymphoid Malignancies Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health Precision Therapy of Lymphoma via Genomics Renier J. Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center CAR T cell Therapy: CARs and Armored CARs Oral Abstract Presenter: James A. Heward, PhD, Barts Cancer Institute, Queen Mary University of London KDM5 Inhibition Is a Novel Therapeutic Strategy for the Treatment of KMT2D Mutant Lymphomas
3:15 p.m. – 3:45 p.m.	Networking Coffee Break
3:45 p.m. – 5:15 p.m.	Poster Presentations
5:15 p.m. – 6:45 p.m.	Dinner (provided)
6:45 p.m. - 8:45 p.m.	Molecular Pathogenesis of T-Cell Lymphoma Chair: Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania Speakers: Laurence L. de Leval, MD, PhD, Lausanne University Hospital Pathology and Genetic Lesions Teresa Palomero, PhD, Columbia University The Role of the RHOA G17V Mutation in the Pathogenesis of Angioimmunoblastic T-Cell Lymphoma (AITL) Megan Lim, MD, PhD, University of Pennsylvania Perelman School of Medicine Novel Insights Into Anaplastic Lymphoma Kinase-Mediated Pathogenetic Mechanisms in Anaplastic Large Cell Lymphoma Oral Abstract Presenters: Sayeef Mirza, MD, University of South Florida Genomic Landscapes of Cutaneous T-Cell Lymphoma and Sezary Syndrome Emmanuel Bachy, MD PhD, Lyon Sud Hospital Whole-Genome Crispr/Cas9 Screens Uncover the C-Terminal Portion of the Long-Isoform of Cflip as Essential for Ptcl Survival

Sunday - August 5

7:00 a.m. – 1:00 p.m.	Registration
7:00 a.m. – 8:00 a.m.	Breakfast and Exhibits
8:00 a.m. – 10:00 a.m.	B-Cell Malignancies Chair: Laura Pasqualucci, MD, Columbia University Speakers: Bertrand Nadel, PhD, Centre D'Immunologie De Marseille-Luminy Integrative Single-Cell Analysis: A New Prism to Decipher Follicular Lymphoma Heterogeneity Ralf Kuppers, PhD, University of Duisburg - Essen Hodgkin Lymphoma Elias Campo, MD, PhD, University of Barcelona Molecular Heterogeneity in Mantle Cell Lymphoma Oral Abstract Presenters: Elena Battistello, Swiss Federal Institute of Technology in Lausanne Multimodal Inhibition of B Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma (DLBCL) Impacts DLBCL Evolution Fen Zhu, University of Wisconsin School of Medicine and Public Health Protein Arginine Methyltransferase 5 Is Upregulated by B Cell Antigen Receptor Signaling and Promotes the Survival of Diffuse Large B-Cell Lymphoma Cells
10:00 a.m. – 10:20 a.m.	Networking Coffee Break
10:20 a.m. – 12:20 p.m.	Chronic Lymphocytic Leukemia Chair: Elias Campo, MD, PhD, University of Barcelona Speakers: Silvia Deaglio, MD, PhD, University of Turin Microenvironmental Interactions in Chronic Lymphocytic Leukemia Davide Rossi, MD, PhD, Oncology Institute of Southern Switzerland Clinical Implications of Gene Mutations in Chronic Lymphocytic Leukemia Francesco Forconi, MD, PhD, University of Southampton B-Cell Receptor-Associated Kinase Inhibitors in Chronic Lymphocytic Leukemia Oral Abstract Presenters: Yong Li, PhD, Cleveland Clinic Non-Proteolytic Polyubiquitination of Myd88 L265p in Class Switching Recombination and B-Cell Oncogenesis Robert N. Booher, PhD, Curis, Inc. Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination With Targeted Therapies in Diffuse Large B-Cell and Mantle Cell Lymphoma
12:20 p.m. – 12:40 p.m.	Closing Remarks From Program Co-Chairs